BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25938558)

  • 1. Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.
    Morin F; Kavian N; Marut W; Chéreau C; Cerles O; Grange P; Weill B; Nicco C; Batteux F
    J Invest Dermatol; 2015 Oct; 135(10):2385-2393. PubMed ID: 25938558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Invest Dermatol; 2016 Nov; 136(11):2158-2167. PubMed ID: 27424318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease.
    Kavian N; Marut W; Servettaz A; Laude H; Nicco C; Chéreau C; Weill B; Batteux F
    J Immunol; 2012 May; 188(10):5142-9. PubMed ID: 22491256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
    Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
    Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
    Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
    J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model.
    Lim JY; Ryu DB; Lee SE; Park G; Min CK
    J Invest Dermatol; 2017 Sep; 137(9):1895-1904. PubMed ID: 28526296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
    Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
    Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
    Zhou L; Askew D; Wu C; Gilliam AC
    J Invest Dermatol; 2007 Feb; 127(2):281-92. PubMed ID: 16917493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
    Askew D; Zhou L; Wu C; Chen G; Gilliam AC
    J Invest Dermatol; 2007 Aug; 127(8):1905-14. PubMed ID: 17429441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
    Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
    PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. October 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    Nusbaum AG; Miteva M
    J Invest Dermatol; 2015 Oct; 135(10):e33. PubMed ID: 26358389
    [No Abstract]   [Full Text] [Related]  

  • 13. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ-Stimulated Apoptotic Keratinocytes Promote Sclerodermatous Changes in Chronic Graft-Versus-Host Disease.
    Saito A; Ichimura Y; Kubota N; Tanaka R; Nakamura Y; Fujisawa Y; Watanabe R; Ishitsuka Y; Fujimoto M; Okiyama N
    J Invest Dermatol; 2021 Jun; 141(6):1473-1481.e4. PubMed ID: 33242500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
    Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
    Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
    Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.
    Hill GR; Olver SD; Kuns RD; Varelias A; Raffelt NC; Don AL; Markey KA; Wilson YA; Smyth MJ; Iwakura Y; Tocker J; Clouston AD; Macdonald KP
    Blood; 2010 Aug; 116(5):819-28. PubMed ID: 20435882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
    Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
    Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.